Abattis Bioceuticals Corp Stock Last Dividend Paid
| ATTBF Stock | USD 0.0001 0.00 0.00% |
Abattis Bioceuticals Corp fundamentals help investors to digest information that contributes to Abattis Bioceuticals' financial success or failures. It also enables traders to predict the movement of Abattis Pink Sheet. The fundamental analysis module provides a way to measure Abattis Bioceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Abattis Bioceuticals pink sheet.
Abattis |
Abattis Bioceuticals Corp Company Last Dividend Paid Analysis
Abattis Bioceuticals' Last Dividend Paid refers to dividend per share(DPS) paid to the shareholder the last time dividends were issued by a company. In its conventional sense, dividends refer to the distribution of some of a company's net earnings or capital gains decided by the board of directors.
More About Last Dividend Paid | All Equity Analysis
Last Dividend | = | Last Profit Distribution AmountTotal Shares |
Many stable companies today pay out dividends to their shareholders in the form of the income distribution, but high-growth firms rarely offer dividends because all of their earnings are reinvested back to the business.
| Competition |
Based on the recorded statements, Abattis Bioceuticals Corp has a Last Dividend Paid of 0.0. This indicator is about the same for the Pharmaceuticals average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Did you try this?
Run Portfolio Anywhere Now
Portfolio AnywhereTrack or share privately all of your investments from the convenience of any device |
| All Next | Launch Module |
Abattis Fundamentals
| Return On Equity | -0.28 | |||
| Return On Asset | -0.16 | |||
| Operating Margin | (10.96) % | |||
| Current Valuation | 4.08 M | |||
| Shares Outstanding | 477.8 M | |||
| Shares Owned By Institutions | 0.02 % | |||
| Price To Earning | (5.83) X | |||
| Price To Book | 0.38 X | |||
| Price To Sales | 1.33 X | |||
| Revenue | 356.88 K | |||
| Gross Profit | 241.34 K | |||
| EBITDA | (2.9 M) | |||
| Net Income | (3.04 M) | |||
| Cash And Equivalents | 2.4 M | |||
| Total Debt | 150.86 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 0.73 X | |||
| Book Value Per Share | 0.02 X | |||
| Cash Flow From Operations | 9.41 M | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 32 | |||
| Beta | -60.6 | |||
| Market Capitalization | 473.03 K | |||
| Total Asset | 19.26 M | |||
| Retained Earnings | (10.13 M) | |||
| Working Capital | (588 K) | |||
| Current Asset | 260 K | |||
| Current Liabilities | 848 K | |||
| Z Score | 1.8 | |||
| Net Asset | 19.26 M |
About Abattis Bioceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Abattis Bioceuticals Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Abattis Bioceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Abattis Bioceuticals Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Abattis Pink Sheet
Abattis Bioceuticals financial ratios help investors to determine whether Abattis Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Abattis with respect to the benefits of owning Abattis Bioceuticals security.